Senseonics (SENS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
9 Apr, 2026Executive summary
The annual meeting will be held virtually on May 20, 2026, with six key proposals up for shareholder vote, including director elections, executive compensation, auditor ratification, an increase in authorized shares, and a new equity incentive plan.
The proxy statement includes detailed information on voting procedures, eligibility, and the rationale for each proposal.
The board recommends voting in favor of all proposals and provides guidance on how to participate and submit questions during the virtual meeting.
Voting matters and shareholder proposals
Shareholders will vote on electing three directors for terms expiring in 2029, approving executive compensation, determining the frequency of say-on-pay votes, ratifying KPMG LLP as auditor, doubling authorized common shares, and approving the 2026 Equity Incentive Plan.
The board recommends voting for all director nominees, for executive compensation, for annual say-on-pay votes, for auditor ratification, for the share increase, and for the new equity plan.
Voting standards and the effect of abstentions and broker non-votes are clearly outlined for each proposal.
Board of directors and corporate governance
The board is divided into three classes, with nine members, and a majority are independent as per Nasdaq rules.
Leadership structure separates the roles of chairman and CEO, with an independent chairman presiding.
The board met eight times in 2025, with high attendance except for one director due to conflict of interest.
Three standing committees (Audit, Compensation, Nominating and Corporate Governance) are fully independent and have defined charters.
Stockholders can communicate directly with the board, and a code of ethics and corporate governance guidelines are in place.
Latest events from Senseonics
- 2025 revenue up 60% to $35.3M, with 65–76% growth expected in 2026.SENS
Q4 202529 Apr 2026 - Key proposals include director elections, share increase, and new equity plan, all board-backed.SENS
Proxy filing6 Apr 2026 - Six key proposals, including share increase and new equity plan, recommended for approval.SENS
Proxy filing6 Apr 2026 - Virtual meeting to vote on directors, compensation, share increase, and new equity plan.SENS
Proxy filing27 Mar 2026 - 2025 guidance projects $34–38M revenue and a doubling of the global patient base.SENS
Q4 202413 Feb 2026 - Q2 2025 revenue up 37% YoY to $6.6M, gross margin at 46.9%, net loss narrowed to $14.5M.SENS
Q2 20253 Feb 2026 - Launching a one-year CGM sensor and expanding partnerships to capture rapid diabetes market growth.SENS
Small-Cap Growth Virtual Investor Conference3 Feb 2026 - Q2 revenue up 18% year-over-year, but losses and funding risks remain as Q4 launch nears.SENS
Q2 20242 Feb 2026 - FDA launch of 365-day CGM spurs demand, but Q3 revenue drops and liquidity risks persist.SENS
Q3 202415 Jan 2026